Geographic Area – Page 20

Grünenthal Acquires US-Based Valinor Pharma for $250 Million

9 months ago talkbio0Tagged Acquisition, Drug Industry, expansion, Grünenthal, Market, Movantik, naloxegol, Pain management, Pharma, U.S., Valinor

Grünenthal, Valinor Pharma, acquisition, Movantik, naloxegol, opioid-induced constipation, pain management, US market expansion, pharmaceutical industry

Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug

9 months ago talkbio0Tagged Biological Factors, China, Diabetes, Eli Lilly, Glucagon-Like Peptide 1, Innovent, mazdutide, Phase 3 trial, Weight Loss

Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China

Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns

9 months ago talkbio0Tagged agonists, China, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Nordisk, Obesity, semaglutide, tirzepatide, Wegovy, Weight Loss, Zepbound

Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy

Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?

10 months ago talkbio0Tagged ABC, Anabolism, Avidity Base Chemistry, Aviti sequencer, Biotechnology, Cloudbreak, competition, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Market, SBS, Sequence Analysis

Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition

Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Response Modifier Therapy, Dermatitis, Atopic, Ebglyss, England, lebrikizumab, Moderate (severity modifier), Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Recommendation, Severe (severity modifier)

Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis

House Speaker Plans Vote on Biosecure Act Amid Broader China Legislation Push

10 months ago talkbio0Tagged biotech, China, House Speaker, National Security, Statutes and Laws

House Speaker, Biosecure Act, China Legislation, National Security, Biotech Companies

Biovance Capital Partners Launches with €51M to Boost Biotech in Southern Europe

10 months ago talkbio0Tagged biotech, Biovance, Capital, Health care facility, Southern Europe, venture

Biovance Capital Partners, Biotech, Southern Europe, Venture Capital, Healthcare

Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans

10 months ago talkbio0Tagged Clayton, fill-finish facility, Irish, Irish (ethnic group), manufacturing site, Nordisk, North Carolina, Obesity, U.S.

Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build

Novo Nordisk Wins Approval in China for GLP-1 Obesity Drug Wegovy

10 months ago talkbio0Tagged China, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide, Wegovy, Weight Loss

Novo Nordisk, Wegovy, GLP-1, Obesity, China, Weight Loss, Semaglutide, Ozempic

CDMO Leaders Unite for Turn-key Drug Production

10 months ago talkbio0Tagged CDMOs, competition, Contract Development, end-to-end services, innovation, Lung consolidation, manufacturing organizations, Market, Pharmaceutical Supply Chain, strategic partnerships, Technology

Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.